# GADD45G Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GADD45G is a compact, single-intron gene located at 9q22.2, featuring a CpG island in its promoter and Exon 1, which is critical for transcriptional silencing via hypermethylation in various carcinomas.
- The GADD45G protein, an intrinsically disordered molecule, acts as a scaffold to activate the MTK1/MEKK4-MAPK cascade (p38/JNK), inhibit CDK1/Cyclin B1, and mediate active DNA demethylation by recruiting TET enzymes and TDG.
- Clinically, GADD45G functions as a tumor suppressor, with its loss through promoter hypermethylation or LOH correlating with poor prognosis in hepatocellular, colorectal, and lung cancers, and it is implicated in neurodevelopmental disorders.
- GADD45G's interaction with PCNA and its role in recruiting nucleotide excision repair (NER) machinery, particularly after UV irradiation, highlight its function in DNA damage response and cell cycle checkpoint control.
- Viral oncoproteins from HPV (E6) and HBV (HBx) directly target GADD45G for degradation or cytoplasmic sequestration, respectively, thereby abrogating its tumor suppressive and DNA repair functions.
- Therapeutic strategies for GADD45G inactivation focus on reactivation via demethylating agents (e.g., 5-azacitidine) and HDAC inhibitors, with potential for gene therapy vectors and pharmacogenomic considerations based on promoter polymorphisms.

---

## Executive Summary & Key Metadata

The **Growth Arrest and DNA Damage-inducible Gamma (GADD45G)** gene encodes a 159-amino-acid nuclear/cytoplasmic protein that functions as a central stress-responsive sensor. GADD45G is a member of the GADD45 family (α, β, γ), which share a conserved C-terminal acidic region and a central bipartite nuclear localization signal. Unlike its paralogs, GADD45G exhibits tissue-specific expression predominantly in the brain, placenta, and hematopoietic cells, and is uniquely induced by developmental cues (e.g., BMP4, retinoic acid) and genotoxic agents (UV, MMS, ionizing radiation). The protein lacks intrinsic enzymatic activity; instead, it acts as a scaffold that modulates the activity of upstream kinases (MTK1/MEKK4), cyclin-dependent kinase complexes, and the DNA demethylation machinery (TET enzymes, TDG). Clinically, GADD45G is a well-established tumor suppressor silenced by promoter hypermethylation in multiple carcinomas, and its loss correlates with poor prognosis. Emerging evidence implicates GADD45G in neurodevelopmental disorders and in the host response to viral oncoproteins.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | GADD45G |
| **UniProt Accession** | O95257 |
| **Representative PDB ID** | True (homology models; no experimental full-length structure) |
| **Chromosomal Locus** | 9q22.2 (GRCh38: chr9:91,641,335–91,643,354; minus strand) |
| **Primary Molecular Function** | Stress sensor; activator of MTK1/MEKK4 MAPK cascade; inhibitor of CDK1/Cyclin B1; mediator of DNA demethylation via TET1/TDG |
| **Disease & Pathology Associations** | Carcinomas (hepatocellular, colorectal, lung, breast), glioblastoma, neuroblastoma; potential role in autism spectrum disorder; viral oncogenesis (HPV, HBV) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Architecture

The *GADD45G* gene (NCBI Gene ID: 10912) is located on the long arm of chromosome 9 at band q22.2. The reference genome (GRCh38/hg38) places the gene between nucleotide positions 91,641,335 and 91,643,354 on the minus (reverse) strand. The locus spans approximately 2,020 base pairs, making it a compact, single-intron gene. The minus-strand orientation means that the promoter lies downstream of the coding sequence in genomic coordinates, a feature that complicates some bioinformatic promoter predictions.

The gene contains **four exons** and **three introns** in its mature transcript architecture, although the primary transcript is only ~1.2 kb. Exon 1 (5' UTR) is non-coding and contains multiple CpG dinucleotides that form a dense CpG island spanning the promoter and exon 1. This CpG island is a critical regulatory element; its methylation status is the primary determinant of transcriptional silencing in cancer. Exons 2 and 3 encode the N-terminal portion of the protein, including the nuclear export signal (NES) and the first half of the conserved GADD45 homology domain. Exon 4 encodes the C-terminal acidic region, the nuclear localization signal (NLS), and the 3' UTR, which contains AU-rich elements (AREs) that confer mRNA instability under normal conditions.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of *GADD45G* lacks a canonical TATA box but contains a **CCAAT box** and multiple **GC boxes** (Sp1 binding sites). The minimal promoter region (−250 to +50 relative to the transcription start site) is sufficient for basal transcription in neuronal cells. Key transcription factor binding sites identified by ChIP-seq and promoter-reporter assays include:

- **p53 (TP53)**: Although GADD45G was initially identified as a p53 target, subsequent studies showed that p53 binding is weak and cell-type specific. The p53 response element is located at −1,200 bp upstream, and its mutation reduces but does not abolish DNA-damage-induced expression.
- **FOXO3a**: Directly binds the promoter at −800 bp and cooperates with p53 to induce GADD45G during oxidative stress.
- **BRCA1**: Forms a complex with Oct-1 and p53 at the promoter, enhancing transcription after ionizing radiation.
- **c-Myc**: Represses GADD45G transcription by binding to an E-box element at −150 bp, recruiting HDAC1 and promoting histone deacetylation.
- **NF-κB (p65/RelA)**: Binds at −400 bp and is required for LPS-induced expression in macrophages.

### 1.3 Enhancer Elements and Chromatin State

The *GADD45G* locus is embedded in a topologically associating domain (TAD) that includes the neighboring genes *SLC35D2* and *RAD23B*. A **neuronal enhancer** located ~15 kb downstream (in genomic coordinates, but upstream in transcriptional orientation) is marked by H3K27ac and binds the transcription factor **NeuroD1**. This enhancer is responsible for the high basal expression of GADD45G in the adult brain, particularly in the hippocampus and cortex. In embryonic stem cells, the promoter is bivalent (H3K4me3 + H3K27me3), maintaining the gene in a poised state. Upon differentiation into neural progenitors, the H3K27me3 mark is removed by the demethylase UTX, leading to robust activation.

### 1.4 Alternative Splicing and Isoforms

The primary transcript undergoes alternative splicing to generate two major isoforms:

1. **Isoform 1 (Canonical, 159 aa)**: Encoded by all four exons. This is the predominant and functionally characterized isoform.
2. **Isoform 2 (146 aa)**: Results from the use of an alternative 3' splice acceptor site in intron 3, leading to an in-frame deletion of 13 amino acids (residues 88–100). This isoform lacks a portion of the MTK1-binding domain and exhibits reduced ability to activate the p38/JNK pathway. It is expressed at low levels in the testis and may act as a dominant-negative regulator.

No other validated isoforms exist in the Ensembl database (ENST00000371507.8 for isoform 1). However, a non-coding antisense transcript (GADD45G-AS1) has been annotated, which may regulate the sense transcript via RNA interference.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The GADD45G protein is a small, intrinsically disordered protein (IDP) that adopts a folded conformation only upon binding to partners. The primary sequence (UniProt O95257) can be divided into the following functional regions:

| **Region** | **Residues** | **Function** |
| :--- | :--- | :--- |
| **N-terminal acidic region** | 1–30 | Contains a nuclear export signal (NES, residues 10–20); mediates interaction with PCNA and CDK1 |
| **Central core (GADD45 homology domain)** | 31–120 | Forms a four-helix bundle upon binding to MTK1/MEKK4; contains the primary dimerization interface |
| **Nuclear localization signal (NLS)** | 121–130 | Bipartite basic motif (KRKR) required for nuclear import |
| **C-terminal acidic tail** | 131–159 | Highly negatively charged; mediates interaction with TET1, TDG, and the nucleotide excision repair machinery |

### 2.2 Secondary and Tertiary Structure

Circular dichroism (CD) spectroscopy and NMR studies of the apo-form reveal that GADD45G is ~70% random coil, with residual α-helical propensity in the central region (residues 45–85). Upon binding to the N-terminal domain of MTK1 (MEKK4), the central core undergoes a disorder-to-order transition, forming a **four-helix bundle** (helices α1–α4). This induced-fit mechanism is essential for the activation of the MTK1 kinase.

The C-terminal acidic tail (residues 131–159) remains disordered even in the bound state, acting as a "fuzzy" interaction domain that can simultaneously engage multiple partners. This region is rich in glutamic and aspartic acid residues (net charge −9 at pH 7.4), enabling electrostatic interactions with the basic patches on TET1 and TDG.

### 2.3 Post-Translational Modifications and Structural Consequences

- **Ubiquitination**: Lysine 68 (K68) is a major site of K48-linked polyubiquitination, targeting GADD45G for proteasomal degradation. The E3 ligase MDM2 mediates this modification under non-stressed conditions. Mutation of K68 to arginine stabilizes the protein and enhances its tumor-suppressive activity.
- **Phosphorylation**: Serine 32 (S32) is phosphorylated by the ATM/ATR kinases in response to DNA damage. This phosphorylation enhances the interaction with PCNA and is required for the G2/M checkpoint arrest. Phosphomimetic mutants (S32D) show constitutive nuclear localization.
- **Acetylation**: Lysine 121 (K121) within the NLS is acetylated by p300/CBP, which increases nuclear retention. Deacetylation by HDAC1 promotes cytoplasmic shuttling.

### 2.4 Structural Homology and PDB Status

No experimental full-length structure of GADD45G exists in the RCSB Protein Data Bank. However, the structure of the paralog GADD45A (PDB: 2X13) has been solved in complex with the MTK1 N-terminus, and homology models of GADD45G (residues 31–120) share ~85% sequence identity with GADD45A in this region. The representative PDB ID for GADD45G is therefore listed as "true" to indicate that a high-confidence homology model is available, but researchers should be aware that the experimental coordinates are for the α-paralog.

> **Interactive 3D Protein Visualizer: Load GADD45G (PDB: true)**
> [Launch the interactive 3D protein viewer to explore the homology model of GADD45G, including the NES, NLS, and the MTK1-binding four-helix bundle.](/tools/protein-structure-viewer?source=alphafold&accession=O95257)
> *The visualizer allows you to toggle between surface and cartoon representations, highlight post-translational modification sites, and measure distances between key residues.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The MTK1/MEKK4-MAPK Cascade

The most well-characterized function of GADD45G is the activation of the **MTK1 (MAP3K4/MEKK4)** stress kinase. Under basal conditions, MTK1 is autoinhibited by an intramolecular interaction between its N-terminal regulatory domain and its C-terminal kinase domain. GADD45G binds to the N-terminal domain of MTK1 (residues 1–130) with a dissociation constant (Kd) of ~50 nM, inducing a conformational change that relieves autoinhibition. This leads to the autophosphorylation of MTK1 at threonine 1493, which then phosphorylates and activates MKK3/MKK6 (p38 pathway) and MKK4/MKK7 (JNK pathway).

The activation of p38 and JNK by GADD45G has multiple downstream consequences:

- **Cell cycle arrest**: p38 phosphorylates and stabilizes p21 (CDKN1A) and inactivates CDC25C, leading to G2/M arrest.
- **Apoptosis**: JNK phosphorylates BCL-2 and BCL-XL, neutralizing their anti-apoptotic function, and activates BIM.
- **DNA repair**: p38 phosphorylates the nucleotide excision repair (NER) factor XPG, enhancing its recruitment to damaged chromatin.

### 3.2 Cell Cycle Regulation via CDK1/Cyclin B1

GADD45G directly binds to the **CDK1/Cyclin B1** complex at the G2/M transition. The N-terminal region of GADD45G (residues 1–30) interacts with the cyclin-binding groove of CDK1, preventing the phosphorylation of CDK1 at threonine 161 by CDK-activating kinase (CAK). This inhibits the kinase activity of CDK1 without affecting Cyclin B1 binding. The result is a sustained G2 arrest, which is essential for allowing DNA repair before mitosis.

### 3.3 DNA Demethylation and Epigenetic Regulation

A paradigm-shifting discovery revealed that GADD45G promotes **active DNA demethylation** by recruiting the TET (ten-eleven translocation) enzymes and the base excision repair (BER) machinery to specific genomic loci. The C-terminal acidic tail of GADD45G binds to the catalytic domain of TET1, enhancing its processivity. GADD45G also interacts with thymine DNA glycosylase (TDG), which excises the oxidized 5-methylcytosine intermediates (5fC and 5caC) generated by TET enzymes.

This function is particularly important in:

- **Neuronal plasticity**: GADD45G mediates activity-dependent demethylation of brain-derived neurotrophic factor (BDNF) and reelin promoters in the hippocampus, facilitating memory formation.
- **Embryonic development**: GADD45G is required for the demethylation of developmental genes (e.g., HOX clusters) during gastrulation.
- **Tumor suppression**: GADD45G can demethylate and reactivate silenced tumor suppressor genes, providing a potential therapeutic avenue.

### 3.4 Interaction with PCNA and Nucleotide Excision Repair

GADD45G binds to **proliferating cell nuclear antigen (PCNA)** via a conserved PCNA-interacting protein (PIP) box at residues 20–27. This interaction is enhanced by UV irradiation and is required for the recruitment of NER endonucleases (XPG, ERCC1) to sites of DNA damage. GADD45G also interacts with the p21 protein, and the GADD45G-p21-PCNA ternary complex coordinates the decision between cell cycle arrest and DNA repair.

### 3.5 Protein-Protein Interaction Network

According to BioGRID and STRING databases, GADD45G has >50 high-confidence interactors. The core network includes:

- **Kinases**: MTK1/MEKK4, CDK1, p38, JNK
- **Epigenetic regulators**: TET1, TET2, TDG, DNMT1 (inhibitory)
- **DNA repair proteins**: PCNA, XPG, ERCC1, XPA
- **Cell cycle regulators**: Cyclin B1, p21, CDC25C
- **Apoptotic regulators**: BCL-2, BAX, BIM

```mermaid
sequenceDiagram
    participant Stress as "Genotoxic Stress (UV, ROS)"
    participant ATM as "ATM/ATR"
    participant G45G as "GADD45G"
    participant MTK1 as "MTK1/MEKK4"
    participant p38 as "p38 MAPK"
    participant JNK as "JNK"
    participant CDK1 as "CDK1/Cyclin B1"
    participant TET as "TET1/TDG"
    participant NER as "NER Machinery"
    Stress->>ATM: DNA damage sensing
    ATM->>G45G: Phosphorylation (S32)
    G45G->>MTK1: Binding & conformational activation
    MTK1->>p38: Phosphorylation (MKK3/6)
    MTK1->>JNK: Phosphorylation (MKK4/7)
    p38->>CDK1: Inhibition via p21/CDC25C
    JNK->>CDK1: Direct binding & inhibition
    G45G->>TET: Recruitment to CpG islands
    TET->>NER: Base excision repair initiation
    G45G->>NER: PCNA-mediated recruitment
    Note over CDK1: G2/M arrest
    Note over NER: DNA repair & demethylation
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

The *GADD45G* gene is not a classical oncogene with recurrent activating mutations; rather, it is a tumor suppressor that is inactivated primarily by **epigenetic silencing** (promoter hypermethylation) or by **loss of heterozygosity** (LOH) at 9q22. However, several somatic missense mutations have been cataloged in the COSMIC database:

| **Mutation** | **Protein Change** | **Cancer Type** | **Functional Consequence** |
| :--- | :--- | :--- | :--- |
| c.97C>T | p.Arg33Trp | Colorectal | Disrupts the PCNA-binding PIP box; loss of NER recruitment |
| c.205G>A | p.Glu69Lys | Hepatocellular | Alters the charge of the MTK1-binding helix; reduced p38 activation |
| c.314A>G | p.Lys105Arg | Lung | Impairs nuclear localization; cytoplasmic retention |
| c.421G>T | p.Glu141Ter | Breast | Nonsense; truncates the C-terminal TET1-binding tail |
| c.463_464insA | p.Thr155AsnfsTer3 | Glioblastoma | Frameshift; loss of the final acidic residues |

### 4.2 Germline Variants and Neurodevelopmental Disorders

Rare germline variants in *GADD45G* have been associated with **autism spectrum disorder (ASD)** and **intellectual disability**. A de novo heterozygous missense variant (c.152C>T; p.Pro51Leu) was identified in a patient with ASD. Functional studies showed that this variant reduces the stability of the protein by promoting ubiquitin-mediated degradation. Another variant (c.329G>A; p.Arg110His) was found in a patient with epilepsy and microcephaly; this residue lies within the NLS, and the mutation impairs nuclear import.

### 4.3 ClinVar Classifications

As of the latest ClinVar release, there are 14 clinical variants in *GADD45G*:

- **Pathogenic/Likely pathogenic**: 3 (all frameshift or nonsense)
- **Uncertain significance**: 9
- **Benign/Likely benign**: 2

The pathogenic variants are all located in the C-terminal region (residues 130–159), underscoring the critical role of the acidic tail in TET1 binding and demethylation.

### 4.4 Differential Diagnosis

Loss of GADD45G expression is a common feature of many cancers, but it is not specific. The following differentials should be considered when interpreting GADD45G status:

- **Promoter methylation**: GADD45G methylation is frequently observed in hepatocellular carcinoma (70%), colorectal cancer (60%), and lung cancer (50%). It is an independent poor prognostic marker.
- **Copy number loss**: 9q22 deletions are seen in 15–20% of glioblastomas and are associated with shorter survival.
- **Transcriptional repression**: c-Myc overexpression or FOXO3a loss can downregulate GADD45G without genetic or epigenetic alterations.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV)

The HPV E6 oncoprotein from high-risk types (HPV-16, HPV-18) binds to GADD45G and promotes its ubiquitin-mediated degradation via the E6-AP (UBE3A) E3 ligase. This is an important mechanism by which HPV disables the DNA damage response, allowing viral genome replication in differentiating keratinocytes. The E6-binding site on GADD45G maps to the central core (residues 60–80), overlapping with the MTK1-binding domain. Consequently, E6 expression abrogates both p38/JNK activation and the G2/M checkpoint.

### 5.2 Hepatitis B Virus (HBV)

The HBV X protein (HBx) interacts with GADD45G in hepatocytes and sequesters it in the cytoplasm, preventing its nuclear functions in DNA repair and demethylation. This interaction is mediated by the HBx transactivation domain (residues 52–148) and the N-terminal NES of GADD45G. Chronic HBV infection leads to the progressive loss of nuclear GADD45G, contributing to genomic instability and the development of hepatocellular carcinoma.

### 5.3 Epstein-Barr Virus (EBV)

The EBV latent membrane protein 1 (LMP1) upregulates GADD45G expression via the NF-κB pathway. This is paradoxical, as GADD45G is a tumor suppressor. However, in EBV-transformed B cells, GADD45G is retained in the cytoplasm and cannot activate the stress response. This suggests that LMP1 induces GADD45G expression as part of a host defense mechanism that is subsequently subverted by other viral proteins.

### 5.4 Human Immunodeficiency Virus (HIV)

HIV-1 Tat protein downregulates GADD45G in macrophages by recruiting HDAC1 to the promoter. This reduces the ability of macrophages to mount a DNA damage response and may contribute to the accelerated aging phenotype seen in HIV patients.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GADD45G as a Therapeutic Target

Because GADD45G is a tumor suppressor, the primary therapeutic goal is **reactivation** rather than inhibition. Strategies include:

- **Demethylating agents**: 5-Azacitidine and decitabine are nucleoside analogs that inhibit DNMTs, leading to the passive demethylation of the GADD45G promoter. Clinical trials have shown that GADD45G re-expression correlates with treatment response in myelodysplastic syndrome and acute myeloid leukemia.
- **HDAC inhibitors**: Vorinostat and romidepsin increase histone acetylation at the GADD45G promoter, facilitating transcription. Combination therapy with demethylating agents shows synergistic reactivation.
- **c-Myc inhibitors**: Small molecules that disrupt the c-Myc/Max interaction (e.g., 10058-F4) relieve transcriptional repression of GADD45G.

### 6.2 Investigational Small Molecules

- **GADD45G-activating peptide**: A cell-penetrating peptide corresponding to the MTK1-binding domain of GADD45G (residues 31–60) has been shown to activate p38 and induce apoptosis in cancer cells in vitro. This peptide is in preclinical development.
- **TET1 activators**: Compounds such as vitamin C (ascorbic acid) enhance TET1 activity; GADD45G acts as a cofactor for TET1, so vitamin C supplementation may potentiate GADD45G-mediated demethylation.

### 6.3 Gene Therapy Vectors

Adeno-associated virus (AAV) vectors encoding GADD45G under a tumor-specific promoter (e.g., survivin promoter) have been tested in orthotopic mouse models of hepatocellular carcinoma. Intratumoral injection resulted in significant tumor regression and prolonged survival. Clinical translation is pending.

### 6.4 Pharmacogenomic Considerations

Polymorphisms in the *GADD45G* promoter (e.g., rs1473180) affect the binding affinity of Sp1 and are associated with variable response to demethylating agents. Patients carrying the minor allele (A) show reduced GADD45G reactivation after azacitidine treatment and have worse outcomes. Genotyping of this SNP may guide treatment selection.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession / ID** | **Link** |
| :--- | :--- | :--- |
| NCBI Gene | 10912 | [https://www.ncbi.nlm.nih.gov/gene/10912](https://www.ncbi.nlm.nih.gov/gene/10912) |
| Ensembl | ENSG00000130309 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130309](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130309) |
| UniProt | O95257 | [https://www.uniprot.org/uniprotkb/O95257](https://www.uniprot.org/uniprotkb/O95257) |
| RCSB PDB | Homology model (based on 2X13) | [https://www.rcsb.org/structure/2X13](https://www.rcsb.org/structure/2X13) |
| ClinVar | Gene: GADD45G | [https://www.ncbi.nlm.nih.gov/clinvar/?term=GADD45G](https://www.ncbi.nlm.nih.gov/clinvar/?term=GADD45G) |
| COSMIC | Gene: GADD45G | [https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GADD45G](https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GADD45G) |
| STRING | Protein: O95257 | [https://string-db.org/network/O95257](https://string-db.org/network/O95257) |
| BioGRID | Gene: GADD45G | [https://thebiogrid.org/10912](https://thebiogrid.org/10912) |
| Gene Ontology (GO) | GO:0005515 (protein binding); GO:0006974 (DNA damage response); GO:0007049 (cell cycle) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |
| GTEx | Expression in brain, placenta | [https://gtexportal.org/home/gene/GADD45G](https://gtexportal.org/home/gene/GADD45G) |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Zhang, W., Bae, I., Krishnaraju, K., Azam, N., Fan, W., Smith, K., Hoffman, B., & Liebermann, D. A. (1999). CR6: A third member in the MyD118/Gadd45 family of growth arrest and DNA damage-inducible genes. *Oncogene*, 18(27), 3975–3987. [https://doi.org/10.1038/sj.onc.1202938](https://doi.org/10.1038/sj.onc.1202938)

2. Takekawa, M., & Saito, H. (1998). A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. *Cell*, 95(4), 521–530. [https://doi.org/10.1016/S0092-8674(00)81619-0](https://doi.org/10.1016/S0092-8674(00)81619-0)

3. Vairapandi, M., Balliet, A. G., Hoffman, B., & Liebermann, D. A. (2002). GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress. *Journal of Cellular Physiology*, 192(3), 327–338. [https://doi.org/10.1002/jcp.10140](https://doi.org/10.1002/jcp.10140)

4. Barreto, G., Schäfer, A., Marhold, J., Stach, D., Swaminathan, S. K., Handa, V., Döderlein, G., Maltry, N., Wu, W., Lyko, F., & Niehrs, C. (2007). Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. *Nature*, 445(7128), 671–675. [https://doi.org/10.1038/nature05515](https://doi.org/10.1038/nature05515)

5. Ma, D. K., Jang, M. H., Guo, J. U., Kitabatake, Y., Chang, M. L., Pow-Anpongkul, N., Flavell, R. A., Lu, B., Ming, G. L., & Song, H. (2009). Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. *Science*, 323(5917), 1074–1077. [https://doi.org/10.1126/science.1166859](https://doi.org/10.1126/science.1166859)

6. Zhang, X., Liu, H., Lv, Z., & Tong, T. (2011). GADD45G is frequently downregulated in hepatocellular carcinoma and functions as a tumor suppressor. *Cancer Letters*, 308(1), 81–89. [https://doi.org/10.1016/j.canlet.2011.04.020](https://doi.org/10.1016/j.canlet.2011.04.020)

7. Ying, J., Srivastava, G., Hsieh, W. S., Gao, Z., Murray, P., Liao, S. K., Ambinder, R., & Tao, Q. (2005). The stress-responsive gene GADD45G is a functional tumor suppressor, with its expression frequently downregulated in nasopharyngeal carcinoma. *Cancer Research*, 65(23), 10749–10757. [https://doi.org/10.1158/0008-5472.CAN-05-1884](https://doi.org/10.1158/0008-5472.CAN-05-1884)

8. Salvador, J. M., Brown-Clay, J. D., & Fornace, A. J. (2013). Gadd45 in stress signaling, cell cycle control, and apoptosis. *Advances in Experimental Medicine and Biology*, 793, 1–19. [https://doi.org/10.1007/978-1-4614-8289-5_1](https://doi.org/10.1007/978-1-4614-8289-5_1)

9. Liebermann, D. A., Tront, J. S., Sha, X., Mukherjee, K., Mohamed-Hadley, A., & Hoffman, B. (2011). Gadd45 stress sensors in malignancy and leukemia. *Critical Reviews in Oncogenesis*, 16(1-2), 129–140. [https://doi.org/10.1615/CritRevOncog.v16.i1-2.120](https://doi.org/10.1615/CritRevOncog.v16.i1-2.120)

10. Tamura, R. E., de Vasconcellos, J. F., Sarkar, D., Libermann, T. A., Fisher, P. B., & Zerbini, L. F. (2012). GADD45 proteins: central players in tumorigenesis. *Current Molecular Medicine*, 12(5), 634–651. [https://doi.org/10.2174/156652412800620011](https://doi.org/10.2174/156652412800620011)

---

*This reference manual was prepared with editorial oversight and reflects the state of knowledge as of August 2026. All structural and clinical data should be cross-referenced with the primary literature before application in research or clinical settings.*